Produção Nacional
Revisado por pares
NCCN Guidelines Insights: Prostate Cancer, Version 1.2021
2021; National Comprehensive Cancer; Volume: 19; Issue: 2 Linguagem: Inglês
10.6004/jnccn.2021.0008
ISSN1540-1413
AutoresEdward M. Schaeffer, Sandy Srinivas, Emmanuel S. Antonarakis, Andrew J. Armstrong, Justin E. Bekelman, Heather H. Cheng, Anthony V. D’Amico, Brian J. Davis, Neil B. Desai, Tanya B. Dorff, James A. Eastham, Thomas A. Farrington, Xin Gao, Eric M. Horwitz, Joseph E. Ippolito, Michael Kuettel, Joshua M. Lang, Rana R. McKay, Jesse K. McKenney, George J. Netto, David F. Penson, Julio M. Pow‐Sang, Robert E. Reiter, Sylvia Richey, Mack Roach, Stan Rosenfeld, Ahmad Shabsigh, Daniel E. Spratt, Benjamin A. Teply, Jonathan D. Tward, Dorothy A. Shead, Deborah A. Freedman-Cass,
Tópico(s)Prostate Cancer Diagnosis and Treatment
ResumoThe NCCN Guidelines for Prostate Cancer address staging and risk assessment after a prostate cancer diagnosis and include management options for localized, regional, and metastatic disease. Recommendations for disease monitoring and treatment of recurrent disease are also included. The NCCN Prostate Cancer Panel meets annually to reevaluate and update their recommendations based on new clinical data and input from within NCCN Member Institutions and from external entities. This article summarizes the panel’s discussions for the 2021 update of the guidelines with regard to systemic therapy for metastatic castration-resistant prostate cancer.
Referência(s)